Squarepoint
AGIO icon

Squarepoint’s Agios Pharmaceuticals AGIO Stock Holding History

Squarepoint’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,000
Closed -$1.2M – 4979
2024
Q3 		$1.2M Hold
27,000
– – ﹤0.01% 2462
2024
Q2 		$1.16M Buy
+27,000
New +$974K ﹤0.01% 2443

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Squarepoint's AGIO Position: Q2 2026 in Review

Squarepoint increased its Agios Pharmaceuticals (AGIO) stake by 54% in Q2 2026, buying an estimated $3.41M and bringing the position to 321,138 shares worth $11.9M. The position accounts for 0.01% of the portfolio, ranked #997.

Squarepoint first reported a position in AGIO in Q2 2017 and has held it in 26 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Squarepoint held 321,138 shares of Agios Pharmaceuticals worth $11.9M as of Q2 2026.
  • Squarepoint bought 112,250 Agios Pharmaceuticals shares in Q2 2026, an estimated $3.41M.
  • Agios Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #997 holding.
  • Squarepoint first reported a position in Agios Pharmaceuticals in Q2 2017 and has held it in 26 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.